Stocktoria

Surrozen, Inc./DE SRZN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-23

Surrozen, Inc./DE statistics & valuation

Market cap$292.8M
P / S84.2×
Net margin-6960.8%
FCF margin-873.5%
Return on capital-47.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-288.00% -596.60% -6960.80% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-354.70% -239.70% -1210.60% 202020212022202320242025
Return on equity (%)
-69.20% -49.80% -47.40% -113.50% 202020212022202320242025
Shares outstanding
18.3M 35.0M 2.0M 2.1M 3.3M 9.8M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-52.70% -39.80% -40.30% -93.40% -131.10% -245.10% 202020212022202320242025
Free cash flow margin (%)
-359.00% -165.70% -873.50% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.21 -$15.56 -$21.33 -$21.67 -$32.37 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-1210.6%-239.7%—-354.7%——
Net margin-6960.8%-596.6%—-288.0%——
FCF margin-873.5%-165.7%—-359.0%——
Return on assets-245.1%-131.1%-93.4%-40.3%-39.8%-52.7%
Return on equity128.9%297.3%-113.5%-47.4%-49.8%-69.2%
Current ratio9.225.325.758.357.756.90

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.